Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330

Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, SPA, for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy